The cluster shows active managers reducing Merck exposure after Q3 earnings that missed EPS consensus, despite a sales beat. The largest seller (Assenagon, -$119.2M) and the absence of insider buying suggest caution. Monitor the Q4 2026 10-K for revenue and EPS trajectory, particularly Keytruda growth sustainability and Winrevair ramp, as well as any further institutional selling in the next 13F cycle.
MRK drugs
MRK drug pipeline →- ● ENFLONSIA 4/10 Approved · PDUFA date Mar 22, 2027
- ● IDVYNSO 4/10 Approved · PDUFA date Apr 22, 2027
- ▲ sac-TMT 6/10 Filed/PDUFA (Phase 3 data complete; BLA under priority review) · PDUFA date Jun 15, 2027
- ● GARDASIL 4/10 Approved
- ● LAGEVRIO 4/10 EUA (Emergency Use Authorization) / Marketed
- 15 more · All MRK drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $144.67entry
- T+1 · 13d ago +3.93%α +2.28% · $150.36
- T+5 · 7d ago +2.34%α +2.92% · $148.05
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
How similar events traded
Executive Summary
A mixed institutional cluster for Merck in Q3 2026 shows three small-to-mid-sized asset managers adding $44.7M in positions while three other managers trimmed $165.1M, for net selling of $120.4M. The cluster follows Q3 earnings reported 5 days ago that beat sales consensus but missed EPS estimates, with narrowed guidance including one-time charges. The selling is concentrated in larger positions (Assenagon alone cut $119.2M), while buying came from smaller funds, creating a net bearish signal from active managers.
Key Financial Metrics
Institutional Positions
Net institutional flow: -$120.4M
▲ Buyers (3)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Exchange Traded Concepts | ADD | +94% | $32.0M | $17.4M |
| Congress Asset Management | DOUBLED | +238.9% | $2.6M | $2.0M |
| Td Waterhouse Canada | ADD | +37% | $69.9M | $25.4M |
▼ Sellers (3)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Alps Advisors | TRIM | -43.7% | $58.2M | -$21.2M |
| Assenagon Asset Management | TRIM | -41.9% | $347.3M | -$119.2M |
| Fort Washington Investment Advisors | TRIM | -37.1% | $85.7M | -$24.8M |
Key Facts
- 3 institutional buyers added $44.7M in new holdings during Q3 2026
- 3 institutional sellers trimmed $165.1M, led by Assenagon Asset Management cutting $119.2M
- Net institutional selling of $120.4M in the quarter
- Q3 2026 earnings (filed Oct 29): sales $18.1B (+5% YoY) beat $17.33B consensus, but GAAP EPS $2.04 missed $2.09 consensus
- Full-year 2026 non-GAAP EPS guidance raised to $2.77-$2.82 but includes $0.12/share in one-time charges
- No open-market insider buying during the quarter (confluence score 9/100, divergent)
- All six funds are asset managers (active), not passive/index funds, strengthening the signal
Financial Impact
Net institutional selling of $120.4M (3 buyers added $44.7M, 3 sellers trimmed $165.1M) in Q3 2026
Risk Factors
- 13F data is 45+ days stale; positions may have been unwound or reversed since quarter-end
- Q3 GAAP EPS miss and one-time charges in guidance may weigh on near-term sentiment
- Patent cliff for Keytruda (2028) remains a long-term overhang despite near-term growth
- Selling by Assenagon ($119.2M) represents a large conviction reduction by a single manager
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-MRK-2026-Q3 |
Track record
34 reports on MRK
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +16.92% at T+20 after the Aug 6, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $147.76 settles Feb 11
- Nov 9, 20268d ago PTAB Trial Neutral 2/10 Entry $148.05 settles Feb 8
- Nov 3, 202613d ago 3 Neutral 2/10 Entry $144.67 settles Feb 1
- Nov 3, 202613d ago Institutional Cluster Bearish 4/10 Viewing Entry $144.67 settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $144.67 settles Feb 1
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $146.33 settles Jan 27
- Oct 22, 202625d ago 3/A Neutral 1/10 Entry $145.27 settles Jan 21
- Oct 21, 202627d ago PTAB Trial Neutral 3/10 Entry $147.24 settles Jan 20
- Oct 15, 20264w ago PTAB Trial Bullish 6/10 Entry $145.95 settles Jan 13
- Oct 15, 20264w ago PTAB Trial Bullish 5/10 Entry $145.95 settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers